European Industry Backs Commitment To Access
A renewed commitment to European access to healthcare made by the European Council has received the backing of industry, which has set out six key policy proposals.
You may also be interested in...
Four pillars to ensure that EU patients can access modern, optimized treatment options offered by the region’s off-patent medicines industry are proposed to incoming policymakers in a manifesto from Medicines for Europe.
Paracetamol, opioids and non-steroidal anti-inflammatory drugs are among the common medicines that “can do more harm than good” and should not be used for managing chronic primary pain, according to a draft NICE guideline.
Sandoz is seeking an en banc rehearing of a recent appeals court decision that stands to keep its Erelzi biosimilar etanercept rival to Enbrel off the market until 2029 in the US, claiming that the ruling provides a “playbook” for originators to extend patents beyond their legitimate terms.